Drugs / GSK2981710
last change Jul 2015 re-read 3 minutes ago

GSK2981710

Developed for
Alzheimer disease
Investigated by
GlaxoSmithKline

Trials 1

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01702480 Nov 2012 → Jul 2015 Alzheimer disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK2981710 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01702480 ↗